Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins.
about
Adjuvant Therapy for Gallbladder Cancer: an Analysis of the National Cancer Data Base.Evaluation of the safety and pathological effects of neoadjuvant full-dose gemcitabine combination radiation therapy in patients with biliary tract cancer.Adjuvant therapy in biliary tract and gall bladder carcinomas: a review.Impact of Chemotherapy and External-Beam Radiation Therapy on Outcomes among Patients with Resected Gallbladder Cancer: A Multi-institutional Analysis.A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer.Technical Aspects of Gallbladder Cancer Surgery2564 resected periampullary adenocarcinomas at a single institution: trends over three decades.Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: a systematic review.Liver transplantation for hilar cholangiocarcinoma.Surgical treatment of gallbladder carcinoma: a critical review.GUIDELINE FOR THE MANAGEMENT OF BILE DUCT CANCERS BY THE BRAZILIAN GASTROINTESTINAL TUMOR GROUP.Incidental Gallbladder Cancer: Residual Cancer Discovered at Oncologic Extended Resection Determines Outcome: A Report from High- and Low-Incidence Countries.Successful radical surgical resection of initially unresectable intrahepatic cholangiocarcinoma by downsizing chemotherapy with gemcitabine plus cisplatin: a case report.Emerging role of multimodality treatment in gall bladder cancer: Outcomes following 510 consecutive resections in a tertiary referral center.Effects of matrix metalloproteinase inhibitor doxycycline and CD147 antagonist peptide-9 on gallbladder carcinoma cell lines.Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium.Patterns of initial failure after resection for gallbladder cancer: implications for adjuvant radiotherapy.Adjuvant Chemoradiotherapy is Associated with Improved Survival for Patients with Resected Gallbladder Carcinoma: A Systematic Review and Meta-analysis.Patterns of failure and determinants of outcomes following radical re-resection for incidental gallbladder cancer.Early gallbladder carcinoma has a favorable outcome but Rokitansky-Aschoff sinus involvement is an adverse prognostic factor.Neoadjuvant Chemoradiation Followed by Surgery for Locally Advanced Gallbladder Cancers: A New Paradigm.Locally Advanced Intrahepatic Cholangiocarcinoma: Complete Pathologic Response to Neoadjuvant Chemotherapy Followed by Left Hepatic Trisectionectomy and Caudate Lobectomy.Tumor-infiltrating neutrophils predict prognosis and adjuvant chemotherapeutic benefit in patients with biliary cancer.Surgical management of hilar cholangiocarcinoma at Memorial Sloan Kettering Cancer CenterNeoadjuvant treatment of biliary tract cancer: state-of-the-art and new perspectivesIs there a role for neoadjuvant and adjuvant therapy in biliary cancer?Concurrent chemoradiation for resected gall bladder cancers and cholangiocarcinomas
P2860
Q30988473-686B73A4-BA62-43D5-9662-1CA9A6FE8C4CQ33427403-1F3F44D0-8C79-4E00-914D-CB32B9A9B121Q33593250-664CE9B5-1626-4E2A-9E90-FAB816EF174BQ33757744-8602DCAA-A7C3-4D5E-8256-72ACF0A892AEQ34484245-84320065-F097-4C50-9E20-3D623C2F72FCQ37002851-C5C818A2-2E2B-4608-B87B-F52E42A03A31Q37480871-ABF1BB16-00A5-4087-915A-F34A49E57933Q38131835-7555C56D-6FFC-46B8-B742-804E36A5F583Q38177254-D43DC177-90B1-420C-85D2-6AEA9C0D8DCCQ38632029-862A01D4-59F6-4017-8742-2829AA8695BAQ38858942-C23B2F6B-AF33-4728-9084-6B960FA2E8A2Q40239322-D04B593C-EDA8-4A84-B758-306513942162Q47135011-EC6B2325-F549-4B7F-8194-E03F1A4AD4E0Q47643887-6A2945C9-F794-4446-8E30-5CC9DA25F30CQ47649561-B5ECEBF4-0CE7-4147-B4F6-EE857688564AQ48336081-4720EF9C-0D60-413A-9BDB-B3486C2CA3D5Q49254989-C1039DC5-AC6B-4B5F-9565-FA8FDFE1CCC1Q50100553-40138E81-BD6F-4EBA-90A2-3CFE17F06BA7Q50186839-80048753-A39C-499A-BA49-2EE8E52D64BEQ50187945-32FEA8E8-F1FC-48BD-AB56-9F31F3153181Q51372660-F1005947-5088-433C-BE2D-D9412854A701Q53018290-E5633543-41E6-4440-A08D-689FACCAE155Q55484842-B493729F-2315-4A33-BE0D-5106D918E39AQ57116389-330F6C0A-85F6-412E-9DFD-E90421FF3C67Q57139983-979B7663-3F14-44B7-8D6F-094694C388D9Q57823336-43B2083B-6029-464A-B0B0-97791125F621Q58806092-BEC6BF84-258A-4180-8EE5-6F0FCE7FB25C
P2860
Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Neither neoadjuvant nor adjuva ...... on with wide negative margins.
@ast
Neither neoadjuvant nor adjuva ...... on with wide negative margins.
@en
Neither neoadjuvant nor adjuva ...... on with wide negative margins.
@nl
type
label
Neither neoadjuvant nor adjuva ...... on with wide negative margins.
@ast
Neither neoadjuvant nor adjuva ...... on with wide negative margins.
@en
Neither neoadjuvant nor adjuva ...... on with wide negative margins.
@nl
prefLabel
Neither neoadjuvant nor adjuva ...... on with wide negative margins.
@ast
Neither neoadjuvant nor adjuva ...... on with wide negative margins.
@en
Neither neoadjuvant nor adjuva ...... on with wide negative margins.
@nl
P2093
P2860
P1476
Neither neoadjuvant nor adjuva ...... on with wide negative margins.
@en
P2093
Eddie K Abdalla
Evan S Glazer
Steven A Curley
P2860
P2888
P304
P356
10.1007/S11605-012-1935-1
P577
2012-07-10T00:00:00Z